Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H28ClN3O4 |
| Molecular Weight | 397.896 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC(=O)CN1CCC(CC1)NC(=O)C2=C(OC)C=C(N)C(Cl)=C2
InChI
InChIKey=AQMLPMSSCWTNNN-UHFFFAOYSA-N
InChI=1S/C19H28ClN3O4/c1-3-4-9-27-18(24)12-23-7-5-13(6-8-23)22-19(25)14-10-15(20)16(21)11-17(14)26-2/h10-11,13H,3-9,12,21H2,1-2H3,(H,22,25)
| Molecular Formula | C19H28ClN3O4 |
| Molecular Weight | 397.896 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Glutamatergic targets for enhancing extinction learning in drug addiction. | 2010-12 |
|
| Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. | 2010-02-11 |
|
| Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. | 2009-11 |
|
| Systematic review of pharmacological treatments in fragile X syndrome. | 2009-10-13 |
|
| Ampakine CX516 ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. | 2008-11 |
|
| Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats. | 2008-06 |
|
| A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. | 2008-02 |
|
| Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. | 2006-10 |
|
| Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. | 2006-06 |
|
| Glutamate-based therapeutic approaches: ampakines. | 2006-02 |
|
| Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. | 2005-04 |
|
| Positive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators have different impact on synaptic transmission in the thalamus and hippocampus. | 2005-04 |
|
| Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. | 2005-01-01 |
|
| Amphetamine-evoked gene expression in striatopallidal neurons: regulation by corticostriatal afferents and the ERK/MAPK signaling cascade. | 2004-10 |
|
| Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. | 2004 |
|
| Cortex Pharmaceuticals, Inc. Maintaining brain function goes a long way. | 2003-11 |
|
| Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors elicits neuroprotection after trimethyltin exposure in hippocampus. | 2002-12-01 |
|
| Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. | 2002-12 |
|
| Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. | 2002-10-01 |
|
| Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report. | 2002-09-06 |
|
| CX-516 Cortex pharmaceuticals. | 2002-07 |
|
| Positive modulators of AMPA receptors as a potential treatment for schizophrenia. | 2002-07 |
|
| Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. | 2002-04-05 |
|
| Survival signaling and selective neuroprotection through glutamatergic transmission. | 2002-03 |
|
| Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546. | 2001-11 |
|
| A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. | 2001-10 |
|
| Therapeutic approaches to age-associated neurocognitive disorders. | 2001-09 |
|
| Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator. | 2001-07 |
|
| Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo. | 2001-06 |
|
| Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. | 2001-06 |
|
| AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. | 2000-04-25 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:42:47 GMT 2025
by
admin
on
Mon Mar 31 23:42:47 GMT 2025
|
| Record UNII |
XVR3JT7PGA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
287399-47-7
Created by
admin on Mon Mar 31 23:42:47 GMT 2025 , Edited by admin on Mon Mar 31 23:42:47 GMT 2025
|
PRIMARY | |||
|
XVR3JT7PGA
Created by
admin on Mon Mar 31 23:42:47 GMT 2025 , Edited by admin on Mon Mar 31 23:42:47 GMT 2025
|
PRIMARY | |||
|
9822171
Created by
admin on Mon Mar 31 23:42:47 GMT 2025 , Edited by admin on Mon Mar 31 23:42:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
